Instantly diagnose and manage respiratory disease using only a smartphone.
We provide point of care diagnostic solutions for telehealth that are easily integrated into existing platforms. We are working on apps to provide instant clinical quality diagnostic tests and management tools directly to consumers and healthcare providers.
A world-leading technology platform
Over the last five years the research team, led by Associate Professor Udantha Abeyratne at The University of Queensland, has pioneered algorithms that accurately characterise the state of patients’ respiratory tracts. The team has created a powerful platform for respiratory disease diagnosis and management which only requires the sound of the patient’s cough or breathing and does not require physical contact. With the high quality microphones in today’s smartphones the platform can be delivered without the need for additional hardware.
Latest Press Releases
April 23, 2019
Positive Results from Australian Prospective Clinical Study Confirm ResApp’s Algorithms Deliver High Accuracy When Diagnosing Respiratory Disease in Adults
April 15, 2019
ResApp Submits De Novo Application to the FDA for Smartphone-based Diagnosis of Paediatric Respiratory Disease
March 29, 2019
March 19, 2019
ResApp announces strong results from Australian pediatric trial of respiratory diagnostic tool
September 4, 2018
Top-line data from the latest trial of ResApp’s smartphone-based diagnostic algorithm for respiratory diseases suggest that the machine learning tool’s conclusions generally align with clinical diagnoses when employed for younger patients. Read the article
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.